Delcath Systems, Inc.NASDAQ: DCTH

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

· Issued by Delcath Systems, Inc. via Business Wire

Summary by 6ix AI

Delcath Systems, Inc., a company focused on treating primary and metastatic liver cancers, granted equity awards on November 2, 2026 as material inducements to three individuals. The awards are restricted stock units (RSUs), rights to receive company shares as they vest, covering a total of 21,250 shares of common stock.

Key details

  • The awards were previously approved by the company's Compensation Committee and are subject to the terms and conditions of the company's 2023 Inducement Plan.
  • One-third of the RSUs vest on the first anniversary of the November 2, 2026 grant date, and the remaining two-thirds vest in equal annual installments over the following two years.
  • The awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

What’s still pending

  • Vesting of the RSUs is subject to each employee's continued employment with Delcath on each vesting date.

6ix AI wrote this summary from the release below and checked it against the release.

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to three individuals whose grant date was in either September 2026 or October 2026.

The grants, in the form of Restricted Stock Units (RSUs), totaled 21,250 shares of the Company’s common stock and are subject to the terms and conditions of the Company’s 2023 Inducement Plan (“Plan”). The RSUs were granted on November 2, 2026 and one-third of the RSUs will vest on the first anniversary of the grant date with the remaining two-thirds of the RSUs vesting in equal annual installments over the following two years. The RSUs are subject to the employee’s continued employment with Delcath on each vesting date.

The above-described awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and granted pursuant to the terms of the Plan.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.

In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT.

In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.

View original source (Business Wire)Delcath Systems, Inc. on 6ix

Story so far

Earlier from Delcath Systems

All Delcath Systems news releases